BerGenBio - Mandatory notification of trade by Primary Insider
Oncoinvent ASA (ONCIN) · publisert 10. januar 2022 kl. 19:52 · vis på NewsWeb
Transaksjoner
| Person | Rolle | Type | Volum | Pris | Dato | ISIN | Handelsplass |
|---|---|---|---|---|---|---|---|
| Martin Olin | CEO | Kjøp | 9 100 | 20,508 NOK | 10. januar 2022 | NO0010650013 | XOSL - Oslo Børs |
Vedlegg
- Release.pdf (application/pdf, originaldokument)
- MO_10_January_2022.pdf (application/pdf, originaldokument)
Meldingstekst
Bergen, Norway,10 January 2022?-BerGenBioASA (OSE: BGBIO) (the "Company"), has
been notified that Martin Olin, CEO and primary insider of BerGenBio ASA, has
bought 9,100 shares in BerGenBio ASA at an average price of NOK 20.51 per share.
After the transaction Mr. Olin holds 37,100 shares in BerGenBio ASA.
Please see the attached document for further details of the transaction.
Contact:
ir@bergenbio.com
RuneSkeie, CFO,BerGenBioASA
rune.skeie@bergenbio.com
This information issubject to the disclosure requirements pursuant to the EU
Market Abuse Regulation (MAR) and section 5-12 of the Norwegian Securities
Trading Act.